IRB #

STUDY00016017

Title

An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Principal Investigator

Matthew Taylor

Study Purpose

This study is being done to test any good or bad effects of rovalpituzumab tesirine in subjects with Delta-like protein 3-expressing melanoma, medullary thyroid cancer (MTC), glioblastoma, large cell neuroendocrine carcinoma (LCNEC), neuroendocrine prostate cancer (NEPC), high-grade gastroenteropancreatc (GEP), neuroendocrine carcinoma (NEC), other NEC, and solid tumors.

Medical Condition(s)

Delta-like protein 3
melanoma, medullary thyroid cancer (MTC)
glioblastoma
large cell neuroendocrine carcinoma (LCNEC)
neuroendocrine prostate cancer (NEPC)
high-grade gastroenteropancreatc (GEP)
neuroendocrine carcinoma (NEC)

Eligibility Criteria

1. Men and women 18 years or older
2. Delta-like protein 3 expressing cancer
3. Adequate organ function
4. Other criteria apply

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Participants will receive the study drug as long as their cancer does not get worse and/or they do not develop side effects that they cannot tolerate. Participants who stop taking study drug due to reasons other than worsening disease will be contacted and have their disease assessed every 6 weeks for the first 6 months, then every 12 weeks until documented worsening disease or until the end of the study. If a participant stops treatment due to worsening disease or completion of study treatment, participants will be contacted every 6 weeks for the first 6 months then every 12 weeks after last dose of study drug(s) until the end of the study.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

AbbVie Stemcentrx Inc

Recruitment End

12/31/2020

Compensation Provided

No


Go Back